Bain Capital

Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

CMIC Holdings is a Japan-based company founded in 1992 and headquartered in Minato-ku, Tokyo. It operates primarily as a contract research organization (CRO) and offers a diverse range of services tailored to the pharmaceutical and healthcare sectors. These services include contract development and manufacturing (CDMO), contract sales organization (CSO) support, and innovative pharmaceutical models (IPM). CMIC specializes in various aspects of pharmaceutical management, encompassing data management, statistical analysis, medical consulting, medical writing, auditing, and analytical testing. Additionally, the company plays a vital role in facilitating clinical trials and providing human resource services, as well as sales and marketing support, thereby contributing significantly to advancements in medical and healthcare fields.

Charta Health is a technology company specializing in medical billing optimization. It employs artificial intelligence to scrutinize patient charts before claims are submitted, ensuring all potential revenue opportunities are captured, claim denials are minimized, and billing standards are consistently met. The platform offers real-time analytics, audits, and autonomous chart reviews, empowering healthcare professionals to enhance administrative efficiency and patient care.

Abcuro, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of autoimmunity and cancer. Established in 2015 and headquartered in Newton, Massachusetts, Abcuro specializes in creating therapeutic antibodies that target novel pathways in these diseases. The company employs advanced bioinformatics to analyze transcription data from human diseases, enabling them to identify new therapeutic targets within the immune system. By leveraging clinical insights and systematic target validation, Abcuro aims to develop immune-modulatory biotherapeutics that provide innovative treatment options for patients suffering from autoimmune disorders and cancer.

Mitsubishi Tanabe Pharma Corporation is a pharmaceutical company headquartered in Osaka, Japan, that manufactures and sells a diverse range of drugs across Japan, Europe, North America, and other Asian countries. The company focuses on developing treatments for various medical conditions, including immuno-inflammation, diabetes, kidney diseases, and central nervous system disorders. Its notable products include Simponi for rheumatoid arthritis, multiple diabetes treatments such as Canaglu and Invokana, Radicava for amyotrophic lateral sclerosis, and Gilenya for multiple sclerosis. Additionally, Mitsubishi Tanabe Pharma offers vaccines, including influenza and varicella vaccines, and over-the-counter products. The company collaborates with several organizations to enhance its research and development capabilities. Founded in 1678, it operates as a subsidiary of Mitsubishi Chemical Holdings Corporation.

Timberlyne Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune diseases. It leverages its team's expertise in drug development to acquire promising assets targeting unmet medical needs. The company specializes in monoclonal antibodies with enhanced complement-dependent cytotoxicity, specifically targeting CD38, a protein highly expressed in various immune cells. This approach enables rapid and durable responses across a range of autoimmune diseases.

Mayapada Hospital offers health and hospital management services. They provide a range of services ranging from diagnosis, therapy, surgery, and rehabilitation to comprehensive care and control of neurological disorders. They offer clinical services and medical consultations for digestive tract problems. Their paediatric centre also provides physical check-ups, vaccinations, and treatment for specific paediatric symptoms, heart failure, and orthopaedic disorders.

Angitia Biopharmaceuticals is a global biotechnology company dedicated to the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company specializes in researching and developing breakthrough therapies for conditions affecting bones, muscles, and joints. By focusing on creating novel drugs, Angitia aims to provide effective treatments that enhance patient recovery from severe musculoskeletal ailments.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Kailera Therapeutics is a biotechnology company focused on developing innovative treatments for obesity and associated conditions. It specializes in injectable and oral GLP-1 (Glucagon-like peptide-1) therapies, aiming to provide patients with transformative health solutions.

Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the health span and lifespan of dogs. The company creates medicines designed to delay the onset of age-related diseases such as cancer, heart disease, and metabolic disorders. By quantifying and regulating the aging process, Loyal seeks to mitigate the effects of aging, thereby promoting healthier and longer lives for dogs. Through its innovative approach, the company aspires to improve the quality of life for pets and enhance their longevity.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for rare diseases, specifically targeting hereditary angioedema (HAE) and other conditions mediated by bradykinin B2 receptors. The company aims to provide alternatives to injectable treatments through its novel small molecules. Pharvaris' lead drug candidate, PHA121, is a potent oral bradykinin B2 receptor antagonist currently undergoing Phase 1 clinical trials. The company's expertise stems from its co-founders, who include key figures involved in the development of icatibant, a well-established treatment for HAE. Pharvaris is committed to addressing significant unmet medical needs in the field of bradykinin-mediated diseases.

Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston that specializes in developing treatments for serious ophthalmic conditions. The company's primary focus is on addressing untreatable diseases of the eye, with its lead drug candidate being an orally delivered compound aimed at treating Stargardt disease and age-related macular degeneration. Through its innovative approach, Alkeus aims to empower medical professionals to manage symptoms of irreversible vision loss at an earlier stage in affected patients.

Emalex Biosciences is a biotechnology startup focused on developing innovative treatments for central nervous system (CNS) disorders and rare neurological conditions. Founded in 2018 by Jeff Aronin, the company is advancing its lead candidate, Ecopipam, which has been explored as a potential therapy for various CNS disorders, including pediatric Tourette Syndrome and fluency disorders. Emalex aims to address the needs of patients with rare diseases that currently have limited or no treatment options, collaborating with patient advocacy organizations and medical researchers to facilitate the development of effective biopharmaceutical therapies.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Topography Health is a company that facilitates the participation of private practice physicians in clinical trials, thereby advancing medical research. It provides a comprehensive platform that assists medical practices in understanding their patient populations and identifying studies that are likely to be accepted and impactful. The company also aids in recruiting patients and managing research staff, effectively addressing the barriers that physicians often face when entering the research field. By enabling local clinical trials, Topography Health offers patients with diverse health conditions access to personalized medical research opportunities for the first time.

Hyperfine is a pioneering medical device company known for developing Swoop, the first FDA-cleared point-of-care MRI system. Swoop is designed to enhance patient access to rapid diagnosis and treatment, regardless of socioeconomic factors or geographic location. This innovative portable MRI system operates at a lower magnetic field strength than traditional MRI machines, allowing for high-quality imaging in a variety of clinical environments. Swoop can be easily transported to a patient's bedside, requires only a standard electrical outlet, and is controlled via an iPad, facilitating quick scans that support critical decision-making in settings such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of its MRI devices as well as service sales, which include subscriptions for bundled devices, maintenance, and software.

Linc'well Inc., founded in 2018 and based in Tokyo, Japan, is a healthcare technology company that develops a software as a service (SaaS) platform tailored for the healthcare industry. The platform offers various digital services including web inquiries, call handling, payment processing, electronic medical records management, and other digitization solutions. Additionally, Linc'well provides clinic operation and management support through its brand CLINIC FORE, along with online support services such as medical supplement subscriptions. These offerings are designed to enhance the efficiency of healthcare institutions and clinics by improving operational processes and patient experiences.

Athenahealth provides a range of internet-based services designed to enhance the operations of medical groups and health systems. The company offers a suite of solutions including athenaCollector for billing and practice management, athenaClinicals for electronic health record management, and athenaCommunicator for automated patient-provider communication. Additionally, it provides athenaCoordinator for care coordination, athenaTelehealth for telemedicine visits, and athenahealth Population Health, which focuses on managing population health data. The platform also features analytics and dashboard applications through athenaOne Analytics, as well as tools for clinical decision support and engagement through services like Epocrates. Athenahealth's integrated software and services aim to improve revenue cycle management, enhance patient engagement, and streamline healthcare operations, ultimately helping healthcare organizations achieve better financial and clinical outcomes. Founded in 1997 and headquartered in Watertown, Massachusetts, Athenahealth was taken private in 2019.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Nautilus Biotechnology Inc. is a development stage life sciences company focused on advancing proteomics to enhance therapeutic development and medical diagnostics. The company aims to create a platform technology that quantifies and unlocks the complexity of the human proteome, ultimately facilitating personalized and predictive medicine. Nautilus has developed a prototype of its innovative single-molecule instrument, the Proteomic Analysis System, which is designed to address challenges in protein analysis that have previously hindered progress in the field. The diverse expertise of its team, which includes professionals from various scientific disciplines such as protein chemistry, molecular biology, and bioinformatics, positions Nautilus to significantly impact drug development and improve human health management.

ConvenientMD LLC is an urgent care provider that specializes in treating non-life-threatening injuries and illnesses. Founded in 2011 and based in Portsmouth, New Hampshire, the company offers a range of services including treatment for sprains, strains, fractures, cuts, colds, bronchitis, and various infections. Additionally, ConvenientMD provides preventive care such as physicals, immunizations, and on-site prescriptions, along with X-ray and laboratory services. Patients can access care without an appointment, with centers open daily from 8 am to 8 pm, ensuring prompt service with minimal wait times. The company operates multiple locations across New Hampshire, Maine, and Massachusetts, emphasizing high-quality medical care delivered by a professional team using advanced medical equipment.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Oncopeptides AB is a biotech company dedicated to developing therapies for challenging-to-treat blood cancers. Its lead compound, melflufen, is a peptide-conjugated alkylator designed to selectively deliver cytotoxic agents into cancer cells, causing rapid and irreversible DNA damage. Melflufen is currently in Phase 2 clinical trials for treating relapsed and relapsed-refractory multiple myeloma. The company's proprietary Peptide Drug Conjugate technology enables targeted delivery of active compounds to diseased cells, enhancing treatment efficacy.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space. The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way. River 3 Renal was established in 2020 in New York, USA.

Multi-Specialty HealthCare operates more than 30 patient care centers throughout the Baltimore-Washington metropolitan area and the Delmarva Peninsula. It employs a patient-centric, integrated model focused on delivering high-quality care to individuals injured in automobile and workplace accidents, regardless of their health insurance status. The company has a team of general practice and urgent care physicians, chiropractors, orthopedists, and other medical specialists who provide a full spectrum of treatment including physical rehabilitation, medical care, and other ancillary services.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for rare diseases, specifically targeting hereditary angioedema (HAE) and other conditions mediated by bradykinin B2 receptors. The company aims to provide alternatives to injectable treatments through its novel small molecules. Pharvaris' lead drug candidate, PHA121, is a potent oral bradykinin B2 receptor antagonist currently undergoing Phase 1 clinical trials. The company's expertise stems from its co-founders, who include key figures involved in the development of icatibant, a well-established treatment for HAE. Pharvaris is committed to addressing significant unmet medical needs in the field of bradykinin-mediated diseases.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Hazel Health, Inc. is a healthcare company focused on enhancing student health and well-being by providing accessible healthcare services. Founded in 2015 and headquartered in San Francisco, California, the company offers a telehealth platform that allows K-12 students to connect with healthcare professionals through live video consultations, whether they are in school or at home. This innovative application enables students to receive timely medical attention for a variety of conditions, with the capability for doctors to prescribe over-the-counter medications at school, pending parental approval. By partnering with schools and their nursing staff, Hazel Health aims to ensure that every child has access to necessary pediatric care, thereby supporting their health and readiness to learn. The company was previously known as HippoMD, Inc. before rebranding in September 2017.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Nurix Therapeutics is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecule therapies aimed at modulating cellular protein levels for the treatment of cancer and immune disorders. The company has developed an integrated discovery platform known as DELigase, which leverages its expertise in E3 ligases—enzymes capable of modulating proteins within cells. Nurix's pipeline includes promising candidates such as NX-2127, an orally available Bruton’s tyrosine kinase degrader targeting relapsed or refractory B-cell malignancies, and NX-1607, an orally available inhibitor of Casitas B-lineage lymphoma proto-oncogene B, intended for immuno-oncology applications. Founded in 2009 and headquartered in San Francisco, California, Nurix Therapeutics was formerly known as Nurix Inc. and rebranded in October 2018. The company has established strategic collaborations with major industry players, enhancing its research and development capabilities.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Kestra Medical Technologies, Inc. is a company that specializes in developing and manufacturing wearable medical devices aimed at monitoring and managing acute medical conditions. Founded in 2014 and headquartered in Kirkland, Washington, the company offers solutions that enable the collection, communication, and storage of patient performance data, facilitating both real-time and retrospective analysis. Among its key products are wearable cardioverter defibrillators designed to prevent sudden cardiac death and aid in the recovery of at-risk cardiac patients. By focusing on intuitive and mobile diagnostic and therapeutic technologies, Kestra Medical Technologies strives to enhance patient care and support healthcare teams in effectively managing patient health.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.

Pharvaris is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for rare diseases, specifically targeting hereditary angioedema (HAE) and other conditions mediated by bradykinin B2 receptors. The company aims to provide alternatives to injectable treatments through its novel small molecules. Pharvaris' lead drug candidate, PHA121, is a potent oral bradykinin B2 receptor antagonist currently undergoing Phase 1 clinical trials. The company's expertise stems from its co-founders, who include key figures involved in the development of icatibant, a well-established treatment for HAE. Pharvaris is committed to addressing significant unmet medical needs in the field of bradykinin-mediated diseases.

Rodeo Dental & Orthodontics, Inc. is a healthcare provider specializing in a comprehensive range of dental services, including general dentistry, orthodontics, endodontics, oral surgery, and pediatric dental care. Founded in 2009 and headquartered in Fort Worth, Texas, the company operates multiple locations across the United States, focusing on delivering quality dental treatments to patients. By offering services such as dental implants and orthodontic care, Rodeo Dental & Orthodontics aims to meet the diverse oral health needs of its clientele, ensuring effective and accessible dental care for individuals and families.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company employs a precision medicine approach to create targeted oncology solutions. Its lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing mirdametinib, an oral small molecule MEK inhibitor, which is undergoing Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also exploring various combination therapies involving nirogacestat and mirdametinib for multiple myeloma and solid tumors. SpringWorks has established collaborations with notable organizations to enhance its research and development efforts, aiming to unlock new treatment options for underserved patient populations.

ImageMoverMD is a medical imaging software company that integrates enterprise imaging and electronic health record systems. The company's innovative solutions employ an exclusive approach to securely connect photos, video, and outside medical images with the EHR, simplifying communication, and enhancing patient care. It transforms enterprise imaging to improve the quality and cost of care while optimizing patient and provider experience. ImagerMoverMD using web-native automation applications that integrate with both the EMR and the VNA/PACs systems, the ImageMover platform measurably improves efficiency, increases revenue capture, and drives HIPAA compliance across the entire care continuum. It also provides end-to-end imaging optimization for health systems.

HealthDrive, founded in 1989 by medical professionals, focuses on delivering on-site medical and dental services to residents of long-term care facilities. With a commitment to enhancing the quality of life for seniors, HealthDrive employs 120 highly skilled providers across a network of over 1,000 facilities, serving more than 135,000 residents nationwide. The company specializes in various healthcare disciplines, including dentistry, optometry, podiatry, and audiology, ensuring that essential services are conveniently available where seniors reside. HealthDrive's approach emphasizes compassionate care and proactive healthcare delivery, making it a leading provider in the long-term care sector.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Centric Health offers an innovative approach to primary healthcare in Ireland, the UK, and Australia, focusing on keeping patients healthy within their communities. The company provides a wide range of accessible medical services that traditionally would have required hospital visits, including community general practice clinics, urgent care facilities, diagnostic imaging centers, and occupational health services. By addressing local healthcare needs proactively, Centric Health aims to enhance patient care and treatment for chronic conditions, ensuring that patients are at the center of their operations.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.

Sansoro Health, Inc. is a healthcare technology company based in Minneapolis, Minnesota, that specializes in integration software for electronic medical record (EMR) platforms. Founded in 2014, the company offers its flagship product, Emissary, which facilitates EMR interoperability through universal application programming interfaces (APIs) and a unified data model. Emissary allows for the integrated display of patient charts from multiple EMRs, enabling real-time clinical analytics alongside web portals and mobile applications. This middleware can be quickly implemented, often within hours, and connects seamlessly with existing EMR systems, significantly reducing costs and operational challenges for healthcare providers. Additionally, Sansoro Health provides tools for monitoring and managing the integration environment, which include advanced security and auditing features, ensuring a streamlined data exchange between electronic health records and clinical administrative applications.

Iodine Software LLC, founded in 2010 and based in Austin, Texas, develops advanced artificial intelligence-based software solutions aimed at enhancing clinical documentation integrity for hospitals across the United States. The company's AwareCDI™ Suite leverages machine learning algorithms to analyze extensive clinical data and documentation, providing predictive insights that assist clinicians and hospital administrators in automating complex tasks. By improving the accuracy and efficiency of clinical documentation, Iodine Software empowers healthcare providers to deliver better patient care while optimizing operational performance. With nearly 500 hospitals utilizing its technology, the company plays a significant role in the transformation of healthcare documentation practices.

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company employs a precision medicine approach to create targeted oncology solutions. Its lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing mirdametinib, an oral small molecule MEK inhibitor, which is undergoing Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also exploring various combination therapies involving nirogacestat and mirdametinib for multiple myeloma and solid tumors. SpringWorks has established collaborations with notable organizations to enhance its research and development efforts, aiming to unlock new treatment options for underserved patient populations.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.

Halo Health Inc. is a technology company that specializes in providing clinical communication and care coordination solutions for healthcare organizations in the United States. The company offers a comprehensive clinical communication platform that includes various tools such as secure messaging for healthcare professionals, an enterprise-wide scheduling system, and patient engagement features. Its offerings, which include Halo Messaging, Halo Pronto, Patient Halo, Halo Handoff, Halo Link, and Halo Patient Coordinator, aim to enhance real-time communication among physicians, nurses, and staff, thereby streamlining patient care. The platform integrates seamlessly with hospital systems, allowing users to access electronic health records, manage on-call schedules, and coordinate care effectively. Halo Health's solutions are designed to improve response times, reduce readmission rates, and facilitate efficient transitions of care. Founded in 2010 and headquartered in Cincinnati, Ohio, Halo Health was previously known as Doc Halo, LLC until it rebranded in May 2018.

Sansoro Health, Inc. is a healthcare technology company based in Minneapolis, Minnesota, that specializes in integration software for electronic medical record (EMR) platforms. Founded in 2014, the company offers its flagship product, Emissary, which facilitates EMR interoperability through universal application programming interfaces (APIs) and a unified data model. Emissary allows for the integrated display of patient charts from multiple EMRs, enabling real-time clinical analytics alongside web portals and mobile applications. This middleware can be quickly implemented, often within hours, and connects seamlessly with existing EMR systems, significantly reducing costs and operational challenges for healthcare providers. Additionally, Sansoro Health provides tools for monitoring and managing the integration environment, which include advanced security and auditing features, ensuring a streamlined data exchange between electronic health records and clinical administrative applications.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Epic Health Services is a prominent provider of home health care, specializing in services for medically fragile children. The company offers a range of pediatric skilled nursing and therapy services, including personal care, behavioral health nursing, and developmental services. In addition to its focus on pediatric care, Epic Health Services also provides various adult home health care services, ensuring comprehensive support for individuals of all ages. Through its dedicated approach, the company aims to enhance the quality of life for its patients and their families.

Navicure’s cloud-based healthcare claims management and patient payment solutions help healthcare organizations of all sizes increase revenue, accelerate cash flow, and reduce costs associated with managing insurance claims and patient payments. Serving more than 90,000 healthcare providers nationwide, Navicure’s technology solutions automate account receivables processes, including claims management; patient eligibility verification; remittance and denial management including automated secondary claims filing, appeals, and posting; reporting and analysis; and patient payment collections at and near the time of service. Navicure’s solutions are supported by its unique 3-Ring® Client Service which guarantees that a client service representative will answer every client call in three rings or less. Navicure is the exclusive billing and patient payment solution of the MGMA Executive Partner network.

Quanterix Corporation is a life sciences company focused on developing an ultra-sensitive digital immunoassay platform to advance precision health in diagnostics and research. Their proprietary technology, Simoa, enables the detection of protein biomarkers at very low concentrations in biological samples such as blood and serum, which are often undetectable using traditional methods. This high level of sensitivity allows for earlier disease detection, improved prognosis, and more precise treatment methods. Quanterix's platforms include bead-based and planar array systems designed to provide reliable and robust assay performance, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research.

Asia Pacific Medical Group operates hospitals and healthcare clinics that deliver a range of medical services to patients in China, Southeast Asia, and beyond. Founded in 1992 by a group of 35 American physicians and surgeons, the organization has rapidly expanded to include 22 clinics and 7 hospitals, establishing itself as a prominent international healthcare provider in the region. The services offered include gamma-knife treatments, neurology and neurosurgery, non-invasive cosmetic dermatology, plastic surgery, and intensity-modulated radiation therapy for various types of tumors, such as those affecting the brain, head and neck, lungs, esophagus, breasts, liver, pancreas, and prostate. Headquartered in Causeway Bay, Hong Kong, Asia Pacific Medical Group is dedicated to providing quality healthcare while ensuring affordability for its patients.

Asia Pacific Medical Group operates a network of hospitals designed to cater to both local and international patients across Southeast Asia. The organization provides a comprehensive range of medical services, including neurology, oncology, cardiovascular medicine, pediatrics, and dermatology. Their facilities are equipped to deliver advanced treatments such as gamma knife therapy, neurosurgery, and plastic surgery, among others. By focusing on affordability, Asia Pacific Medical Group aims to make high-quality healthcare accessible, allowing patients to receive effective treatment for various medical conditions in a supportive environment.

4moms is a company based in Pittsburgh, Pennsylvania, that specializes in developing innovative robotics technology-based products for children from prenatal to preschool age. The company focuses on addressing the real needs of parents by creating advanced juvenile products. Its diverse product line includes various baby and kids items, such as gear, toys, and clothing. With a dedicated team of over forty engineers, designers, and developers, 4moms has successfully established its presence in more than 500 retail locations across 24 countries. By leveraging robotics technology, 4moms aims to enhance the experience of parenting within the growing juvenile products industry, which is valued at approximately 8.9 billion dollars in the U.S.

4moms is a company based in Pittsburgh, Pennsylvania, that specializes in developing innovative robotics technology-based products for children from prenatal to preschool age. The company focuses on addressing the real needs of parents by creating advanced juvenile products. Its diverse product line includes various baby and kids items, such as gear, toys, and clothing. With a dedicated team of over forty engineers, designers, and developers, 4moms has successfully established its presence in more than 500 retail locations across 24 countries. By leveraging robotics technology, 4moms aims to enhance the experience of parenting within the growing juvenile products industry, which is valued at approximately 8.9 billion dollars in the U.S.

National Cardiovascular Partners is an operator of outpatient endovascular, vascular, and cardiovascular services, focusing on providing care in a convenient setting. Partnering with over 200 physicians, the company manages 21 outpatient vascular centers across six states. Its facilities include independent cardiac catheterization and vascular labs, where physician entrepreneurs serve as majority stakeholders, retaining both clinical and financial control. National Cardiovascular Partners oversees the administrative aspects of these centers, allowing physician partners to concentrate on delivering high-quality and innovative patient care.

Plasma Resources UK is a health company that provides health and allied services.

Quanterix Corporation is a life sciences company focused on developing an ultra-sensitive digital immunoassay platform to advance precision health in diagnostics and research. Their proprietary technology, Simoa, enables the detection of protein biomarkers at very low concentrations in biological samples such as blood and serum, which are often undetectable using traditional methods. This high level of sensitivity allows for earlier disease detection, improved prognosis, and more precise treatment methods. Quanterix's platforms include bead-based and planar array systems designed to provide reliable and robust assay performance, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research.

4moms is a company based in Pittsburgh, Pennsylvania, that specializes in developing innovative robotics technology-based products for children from prenatal to preschool age. The company focuses on addressing the real needs of parents by creating advanced juvenile products. Its diverse product line includes various baby and kids items, such as gear, toys, and clothing. With a dedicated team of over forty engineers, designers, and developers, 4moms has successfully established its presence in more than 500 retail locations across 24 countries. By leveraging robotics technology, 4moms aims to enhance the experience of parenting within the growing juvenile products industry, which is valued at approximately 8.9 billion dollars in the U.S.

Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. Founded in 2010 and headquartered in Los Angeles, California, the company primarily focuses on the treatment of various forms of cancer, particularly through its lead product, NERLYNX, an oral formulation of neratinib designed for HER2-positive breast cancer patients. Additionally, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets the epidermal growth factor receptors HER1, HER2, and HER4. The company operates under a licensing agreement with Pfizer for the development and commercialization of its drug candidates, including oral and intravenous forms of neratinib, as well as PB357. With a commitment to enhancing treatment outcomes, Puma Biotechnology is focused on advancing its clinical programs and bringing effective therapies to market for cancer patients.

ABILITY Network Inc. is a healthcare information technology company that focuses on simplifying the administrative and clinical complexities faced by healthcare providers and payers. Founded in 2000 and based in Minneapolis, Minnesota, the company offers a range of services including billing, Medicare claims processing, revenue cycle management, and patient payment solutions. It also provides eligibility verification services and workforce management tools such as scheduling and credentialing. By connecting thousands of hospitals, skilled nursing facilities, and healthcare providers through a secure web-based network, ABILITY Network facilitates millions of transactions daily, earning the trust of both healthcare providers and governmental entities like Medicare. The company serves a diverse clientele, including health systems, clinics, and home health agencies, positioning itself as a vital player in the healthcare technology landscape.

Boston Heart Diagnostics is a healthcare company based in Framingham, Massachusetts, specializing in cardiovascular disease management. The company offers a comprehensive range of laboratory techniques, including gas chromatography, gel electrophoresis, genetic testing, and liquid chromatography. Its proprietary lipid testing technology enables ongoing monitoring of patients' conditions and facilitates the precise selection of effective pharmaceutical treatments for dyslipidemia. Unlike traditional lipid testing methods that focus primarily on initial screenings and may take up to six months to assess treatment efficacy, Boston Heart's approach allows for evaluations within the first six weeks. By combining advanced therapy guidelines and patient support services, Boston Heart Diagnostics aims to provide personalized treatment options that enhance patient health and improve disease management outcomes.

1-800-DENTIST® is only the best way to find a dentist, period. We are the #1 FREE service that custom matches you to your perfect dentist based on your unique dental and payment needs. No other company has more experience or resources dedicated to helping you find the right dentist right away. Since 1986, 1-800-DENTIST has matched over 7 million people to their perfect dentist. With thousands of pre-screened dentists nationwide, we can help you schedule an appointment with a quality, local dentist in just minutes. In addition to helping people find quality dental care in their community, we also offer dentists specialized tools to help them manage their practices and communicate better with their patients. Thanks to 1800dentist.com, you can find the right dentist quicker and easier than ever. Our website provides up-to-date dental information on treatments, such as teeth whitening, dentures and dental braces. Plus, 1800dentist.com offers dental videos for quick oral health tips. If “live” help is more your style, you can always call one of 1-800-DENTIST’s friendly operators any day of the week, 24 hours a day to find a dentist near you.

Helomics Corporation is a personalized healthcare company based in Pittsburgh, Pennsylvania, focused on enhancing cancer care through a range of innovative diagnostic products and services. The company has developed the Precision Cellular Analytical Platform, which analyzes cell cycle and proliferation data over a 25-35 day period. Helomics' offerings include ChemoFx, which assists in selecting effective treatments for gynecologic cancer, and BioSpeciFx, a set of biomarker tests that provide insights into tumor characteristics and potential drug responses. Additionally, Helomics provides GeneFx Colon and GeneFx Lung, microarray-based gene signatures tailored for patients with stage two colon cancer and early-stage non-small cell lung cancer, respectively. The company also engages in tumor profiling services, including bioinformatics and contract research, to support clinical decision-making. Furthermore, Helomics utilizes its D-CHIP digital clinical health insight platform to deliver personalized oncology roadmaps and collaborates with pharmaceutical and diagnostics companies to enhance patient selection for clinical trials. Founded in 1995 and formerly known as Precision Therapeutics, Helomics continues to push the boundaries of precision oncology.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Celerion is a clinical research organization that specializes in early-stage clinical trials and applied translational medicine services for pharmaceutical and biotechnology companies worldwide. Founded in 2010 and headquartered in Lincoln, Nebraska, with additional locations in Tempe, Arizona, and West Conshohocken, Pennsylvania, Celerion focuses on translating research discoveries into actionable insights about drug effects in humans to support early drug development decisions. The company offers a range of services including global clinical research, data management, biometrics, bioanalytical services, and drug development solutions. With over 600 beds for clinical trials and experienced scientific staff, Celerion aims to expedite the market entry of new medicines through innovative strategies and efficient data generation.

Celerion is a clinical research organization that specializes in early-stage clinical trials and applied translational medicine services for pharmaceutical and biotechnology companies worldwide. Founded in 2010 and headquartered in Lincoln, Nebraska, with additional locations in Tempe, Arizona, and West Conshohocken, Pennsylvania, Celerion focuses on translating research discoveries into actionable insights about drug effects in humans to support early drug development decisions. The company offers a range of services including global clinical research, data management, biometrics, bioanalytical services, and drug development solutions. With over 600 beds for clinical trials and experienced scientific staff, Celerion aims to expedite the market entry of new medicines through innovative strategies and efficient data generation.

Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

Enclarity is a provider of information management and analytic software services tailored for the healthcare industry. The company addresses the challenge of maintaining accurate healthcare provider information by maintaining the largest and most current medical provider database. Its offerings include ProviderPoint, a hosted solution for healthcare providers; a version of ProviderPoint specifically for medical device manufacturers; Physician Office Attributes; ProviderLookup, a web-based search service for provider information; and Provider SelectFile, a subscription service that delivers timely provider information based on specific needs. Enclarity's solutions are utilized by several major health insurance plans, preferred provider organizations, and leading medical device manufacturers to enhance claims processing, provider directories, regulatory compliance, and marketing efforts.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Quanterix Corporation is a life sciences company focused on developing an ultra-sensitive digital immunoassay platform to advance precision health in diagnostics and research. Their proprietary technology, Simoa, enables the detection of protein biomarkers at very low concentrations in biological samples such as blood and serum, which are often undetectable using traditional methods. This high level of sensitivity allows for earlier disease detection, improved prognosis, and more precise treatment methods. Quanterix's platforms include bead-based and planar array systems designed to provide reliable and robust assay performance, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research.

Ameritox is a U.S.-based company established in 1996 that specializes in pain medication monitoring services. It provides laboratory services and practice management tools designed to assist clinicians in coordinating and optimizing care for patients suffering from chronic pain. In addition to its core offerings, Ameritox supports healthcare providers with expert guidance and resources, facilitating improved patient management. The company is recognized for its innovative research programs, collaborating with academic institutions and pain centers to advance the field of pain medication monitoring.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Accelecare Wound Centers, located near Seattle, Washington, specializes in comprehensive wound care and disease management. The company partners with hospitals and skilled nursing facilities across the United States to deliver advanced wound-care services. Accelecare operates state-of-the-art Advanced Wound Centers, staffed by trained physicians, nurses, and specialized technicians, who provide effective and cost-efficient wound treatments. The company's focus is on ensuring positive patient outcomes while maintaining high standards of clinical excellence in its care services.

Enclarity is a provider of information management and analytic software services tailored for the healthcare industry. The company addresses the challenge of maintaining accurate healthcare provider information by maintaining the largest and most current medical provider database. Its offerings include ProviderPoint, a hosted solution for healthcare providers; a version of ProviderPoint specifically for medical device manufacturers; Physician Office Attributes; ProviderLookup, a web-based search service for provider information; and Provider SelectFile, a subscription service that delivers timely provider information based on specific needs. Enclarity's solutions are utilized by several major health insurance plans, preferred provider organizations, and leading medical device manufacturers to enhance claims processing, provider directories, regulatory compliance, and marketing efforts.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Nanosphere, Inc. is a healthcare company specializing in the development, manufacturing, and marketing of molecular diagnostic tests for infectious diseases and drug resistance markers. Founded in 1998 and headquartered in Northbrook, Illinois, Nanosphere offers the Verigene System, a molecular diagnostics platform that enables sensitive genomic and protein testing from a single workstation. This system allows for rapid testing—typically completed in hours rather than days—enhancing disease detection and optimal patient treatment. The Verigene System incorporates innovative microfluidics technology, utilizing gold nanoparticles to capture proteins and nucleic acids from clinical samples, such as blood. Nanosphere primarily serves hospital-based laboratories and academic research institutions across the United States, aiming to improve healthcare outcomes and economics through advanced diagnostic capabilities. As of June 2016, Nanosphere operates as a subsidiary of Luminex Corporation.